Neurofibromatosis type 2

International Journal of Clinical Practice

Volumn 57, Issue 8, 2003, Pages 698-703

  Uppal, S ^a   Coatesworth, A P ^a  

^a YORK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MERLIN;

AUDIOMETRY; AUDITORY REHABILITATION; BRAIN ARACHNOID CYST; CHROMOSOME 22; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; EPIDERMOID TUMOR; GENE MUTATION; GENETIC SCREENING; HUMAN; LIPOMA; MENINGIOMA; NEURILEMOMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW;

CHROMOSOMES, HUMAN, PAIR 22; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2; NEUROMA, ACOUSTIC;

EID: 0242490884     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Ahn MS, Jackler RK, Lustig LR. The early history of the neurofibromatoses: evolution of the concept of neurofibromatosis type 2. Arch Otolaryngol Head Neck Surg 1996; 122: 1240-1249.
2. National Institutes of Health Consensus Development Conference. Neurofibromatosis conference statement. Arch Neurol 1998; 45: 575-578.
3. Evans DGR, Huson SM, Donnai D et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. 1. Prevalence, mutation rate, fitness and confirmation of maternal transmission effect on severity. J Med Genet 1992; 29: 841-846.
4. King TT, Gibson WPR, Morrison AW. Tumours of the VIIIth cranial nerve. Br J Hosp Med 1976; 16: 259-272.
5. Sandifort E. Observationes anatomico-pathologicae. Leiden. Netherlands: Ludguni-Batavorum 1777; 116-120
6. Wishart JH. Case of tumours in the skull, dura mater and brain. Edin Med Surg J 1822; 18: 393.
7. Mosse A, Cavalie. Tumeurs multiples de l'enephle et de la moelle allongee: neurofibromatose centrale. Gaz Hebd Med Chir 1897; 2: 789.
8. Feiling A, Ward E. A familial form of acoustic neuroma. BMJ 1920; 1: 496-497.
9. Barker D, Wright E, Nguyen L et al. Gene for von Recklinghausen neurofibromatosis is the pericentromeric region of chromosome 17. Science 1987; 236: 1100-1102.
10. Rouleau GA, Wertelecki W, Haines JL et al. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 1987; 329: 246-248.
11. Evans DG, Huson SM, Donnai D et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet 1992; 29: 847-952.
12. Rouleau GA, Merel P, Lutchman M et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993; 363: 515-521.
13. Trofatter JA, MacCollin MM, Rutter JL et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72: 791-800.
14. Gonzalez-Agosti C, Xu L, Pinney D, Beauchamp R et al. The merlin tumor suppressor localises preferentially in membrane ruffles. Oncogene 1996; 13: 1239-1247.
15. Vaheri A, Carpen O, Heiska L et al. The ezrin protein family: membrane cytoskeleton interactions and disease associations. Curr Opin Cell Biol 1997; 9: 659-666.
16. Lutchman M, Rouleau GA. The neurofibromatosis type 2 gene product, schwannnomin, suppresses growth of NIH 3T3 cells. Cancer Res 1995; 55: 2270-2274.
17. Kim H, Lim JY, Kim YH et al. Inhibition of ras-mediated activator protein 1 activity and cell growth by merlin. Mol Cells 2002; 14(1): 108-114.
18. Schulze KM, Hanemann CO, Muller HW et al. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum Mol Genet 2002; 11(1): 69-76
19. Irving RM, Moffat DA, Hardy DG et al. Molecular genetic analysis of the mechanism of tumorigenesis in acoustic neuroma. Arch Otolaryngol Head Neck Surg 1993; 119: 1222-1228.
20. Welling DB, Guida M, Goll F et al. Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas. Hum Genet 1996; 98: 189-193.
21. Merel P, Hoang-Xuan K, Sanson M et al. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 1995; 13: 211-216.
22. Kluwe L, Mautner VF. A missense mutation in the NF-2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2. Hum Genet 1996; 97: 224-227.
23. Ruttledge MH, Andermann AA, Phelan CM et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996; 59: 331-342.
24. Chan CC, Koch CA, Kaiser-Kupfer MI et al. Loss of heterozygosity for the NF2 gene in the retinal and optic nerve lesions of patients with neurofibromatosis 2. J Pathol 2002; 198(1): 14-20.
25. Parry DM, MacCollin MM, Kaiser-Kupfer MI et al. Germ-like mutations in the neurofibromatosis 2 gene: correlation with disease severity and retinal abnormalities. Am J Hum Genet 1996; 59: 529-539.
26. Mohyuddin A, Neary WJ, Wallace A et al. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. J Med Genet 2002; 39(5): 315-322.
27. Lanser MJ, Sussman SA, Frazer K. Epidemiology, pathogenesis, and genetics of acoustic tumors. Otolaryngol Clin North Am 1992; 25: 499-520.
28. Clemis JD, Ballad WJ, Baggot PJ et al. Relative frequency of inferior vestibular schwannoma. Arch Otolaryngol Head Neck Surg 1986; 112: 190-194.
29. Sterhers JM, Perre J, Viala P et al. The origin of acoustic neuromas. Acta Otolaryngol 1987; 103: 427-431.
30. Luetje CM, Whitaker CK, Calloway LA et al. Histological acoustic tumor involvement of the VIIth nerve and multi-centric involvement of the VIIIth. Laryngoscope 1983; 93: 1133-1139.
31. Sobel RA. Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases. J Neuropathol Exp Neurol 1993; 52: 106-113.
32. Evans D, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 1999; 81(6): 496-499.
33. Eldridge R, Parry DM, Kaiser-Kupfer MI. Neurofibromatosis 2 (NF2): clinical heterogeneity and natural history based on 39 individuals in 9 families and 16 sporadic cases. Abstract. Am J Hum Genet 1991; 49(suppl): 133.
34. Ruttledge MH, Sarrazin J, Rangaratnam S et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nature Genet 1994; 6: 180-184.
35. Evans DGR, Huson SM, Donnai D et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992; 84: 603-618.
36. Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 1988; 318: 684-688.
37. Neary WJ, Newton VE, Vidler M el al. A clinical, genetic and audiological study of patients and families with bilateral acoustic neurofibromatosis. J Laryngol Otol 1993; 107: 6-11.
38. Gardner WJ, Turner O. Bilateral acoustic neurofibromas: further clinical and pathological data on hereditary deafness and Recklinghausen's disease. Arch Neurol Psychiatry 1940; 44: 76-99.
39. Young DF, Eldridge R, Gardner WJ. Bilateral acoustic neuroma in a large kindred. JAMA 1970; 212: 347-353.
40. Baser ME, Mautner VF, Ragge NK et al. Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations. Neurology 1996; 47(5): 1269-1277.
41. Mueller DP, Gantz BJ, Dolan KD. Gadolinium-enhanced MR of the postoperative internal auditory canal following acoustic neuroma resection via the middle fossa approach. Am J Neuroradiol 1992; 13: 197-200.
42. Irving RM. The molecular pathology of tumours of the ear and temporal bone. J Laryngol Otol 1998; 112: 1011-1018.
43. Glasscock ME III, Hart MJ, Vrabeck JT. Management of bilateral acoustic neuroma. Otolaryngol Clin North Am 1992; 25: 449-469.
44. Samii M. Hearing preservation in bilateral acoustic neurinomas. Br J Neurosurg 1995; 9(3): 413-424.
45. Wigand ME, Haid T, Goertzen W et al. Preservation of hearing in bilateral acoustic neurinomas by deliberate partial resection. Acta Otolaryngol 1992; 112: 237-241.
46. Ito K, Kurita H, Sugasawa K et al. Analyses of neuro-otological complications after radiosurgery for acoustic neurinomas. Int J Radiat Oncol Biol Phys 1997; 39(5): 983-988.
47. Thomsen J, Tos M, Bougesen S. Gamma knife: hydrocephalus as a complication of the stereotactic radiosurgical treatment of acoustic neuroma. Am J Otol 1990; 11: 330-333.
48. Hulka GF, Bernard EJ, Pillsbury HC. Cochlear implantation in a patient after removal of an acoustic neuroma: the implications of magnetic resonance imaging with gadolinium on patient management. Arch Otolaryngol Head Neck Surg 1995; 121(4): 465-468.
49. Lane H, Perkell J, Wozniak J et al. The effect of changes in hearing status on speech sound level and speech breathing: a study conducted with cochlear implant users and NF2 patients. J Acoust Soc Am 1998; 104(5): 3059-3069.
50. Tono T, Ushisako Y, Morimitsu T. Cochlear implantation in an intralabyrinthine acoustic neuroma patient after resection of an intracanalicular tumour. J Laryngol Otol 1996; 110(6): 570-573.
51. Friedman RA, Brackmann DE, Mills D. Auditory-nerve integrity after middle-fossa acoustic-tumor removal. Otolaryngol Head Neck Surg 1998; 119(6): 588-592.
52. Josey AF, Glasscock ME 3rd, Musiek FE et al. Correlation of ABR and medical imaging in patients with cerebellopontine angle tumors. Am J Otol 1988; 9: 12-16.
53. Arriaga MA, Long S, Nelson R. Clinical correlates of acoustic neuroma volume. Am J Otol 1993; 14: 465-468.